Smart science to improve lives™


Lipids are organic, nonpolar molecules that play key roles in various aspects of drug formulation and delivery. They can be used as vehicles for solubilising active pharmaceutical ingredients, components for creating lipid based delivery systems like liposomes or agents which can be used in lipid-DNA transfection. Lipids are a versatile classification of macromolecules that can be also be tailored to meet the needs of a number of different applications and conditions.

Speak to an expert

Lipid based drug delivery systems

We offer a wide range of lipids and lipid derivatives to meet the needs of our customers. Additionally, we are proud to extend our product offering to include Avanti Polar Lipids’ extensive portfolio of high purity and specialized lipids and adjuvants, furthering our commitment to bringing innovation in the hands of our customers to help them in getting groundbreaking therapies to market.

As the Lipid Technology segment of the Croda Pharma business, Avanti is primarily focused on developing innovative lipid-based products to address specific medical challenges that are not resolved by current technology or drug products.

Curious about how our lipid technology can aid your drug delivery research? 

For over 30 years, Avanti has been working with the pharmaceutical and diagnostic industry to provide solutions that save or improve lives. We were integrally involved in the development of liposomal-based drug delivery systems and over the past decade we have concentrated on developing lipid components used in Lipid Nanoparticle (LNP) delivery technology to solve the stability and delivery issues associated with mRNA-based vaccines and therapeutics.  

LNPs are lipid-based drug delivery systems that carry nucleic acid material. These systems primarily rely on four lipid components: a PEG lipid, amino (cationic) lipid, structural lipid, and cholesterol.  

The cationic lipids are used to sequester the genetic material through a charge-charge interaction. This is encapsulated by the structural lipid and functionalized on the exterior with PEG lipids. Genetic material is highly susceptible to RNAse activity but the LNP protects the genetic material from degradation. The LNP also allows the genetic material to gain access to the cell and once inside, to be released.  This allows the cellular machinery to translate the delivered genetic material into a cellular response.  

When conducting LNP formulation research there are many important factors to consider including size and shape, surface charge, hydrophobicity, and surface functionalization. Avanti offers a wide variety of cGMP manufactured lipids that will allow you to perfectly tailor your drug delivery systems. As always, these lipids are manufactured to meet the Avanti purity standard of 99% purity. 

WHITEPAPER: Lipid technology for delivery of gene-editing therapies

Lipid delivery for delivery gene-editing therapies
726.4 KB

WHITEPAPER: Innovative lipids for Nucleic Acid Delivery

innovative lipids for your nucleic acid delivery research whitepaper by Croda Pharma
6.0 MB

Your innovative lipids partner

Your innovative lipids partner, Avanti Polar Lipids, Croda Pharma
554.5 KB

If you have a lipid-based drug delivery problem that needs to be solved, reach out to us! We can help you with:

image in circle of people working in a lab

The supply of GMP lipids for your lipid nanoparticle formulation

circular icon of a chemical manufacturing plant

Contract manufacturing of proprietary lipids and formulation development

Analytical services to support clinical development

Did you miss our latest posts?

lipid nanoparticle cross section

Innovative lipids for your nucleic acid delivery research

Lipid-based therapeutic delivery systems have been evolving for many years. From delivering naked mRNA, to using liposomes, and now lipid nanoparticles,

Dr Stephen Burgess PHD, Head of Nucleic Acid Delivery, Croda Pharma, Avanti Polar Lipids

Lipid technology for delivery of gene editing therapies

Gene-editing is one of the most eagerly anticipated biopharma developments in recent history. However, one of the biggest hurdles to the development of successful gene-editing therapeutics is effective delivery of the large and sensitive components needed to execute the editing functions. Lipid-based nanoparticles present promising solutions to these challenges.

headshot of Dennis Christenson

Lipid Leaders: Dennis Christensen

In this Lipid Leaders interview, we get insight from Croda Pharma's own Global Head of R&D - Adjuvant Systems, Dennis Christensen, PhD. Keep reading to learn more about adjuvants and the role they play in vaccines, as well as where the technology may be heading.

Sustainably sourced squalene banner